U.S. patent application number 12/170859 was filed with the patent office on 2008-12-04 for intraorally rapidly disintergrating tablets and their production.
This patent application is currently assigned to NIPPON SHINYAKU CO., LTD. Invention is credited to Tomio NAKANO, Tomoharu SUGA.
Application Number | 20080299192 12/170859 |
Document ID | / |
Family ID | 32767327 |
Filed Date | 2008-12-04 |
United States Patent
Application |
20080299192 |
Kind Code |
A1 |
SUGA; Tomoharu ; et
al. |
December 4, 2008 |
Intraorally Rapidly Disintergrating Tablets and Their
Production
Abstract
The object of the present invention is to provide, as a solid
preparation for making it easy to take, thus improving patient's
compliance etc., an intraorally rapidly disintegrating tablet which
can be produced easily without any particular problem by a usual
method of producing tablets with a usual tabletting machine, has
practically unproblematic hardness, and disintegrate rapidly in the
oral cavity. This tablet is produced by tabletting cores coated
with a pharmaceutical disintegrating agent, wherein the core is a
granule containing a water-soluble medicament or containing a
medicament and a sugar.
Inventors: |
SUGA; Tomoharu; (Kyoto-shi,
JP) ; NAKANO; Tomio; (Osada, JP) |
Correspondence
Address: |
DREIER LLP;Susan Formicola
499 PARK AVE
NEW YORK
NY
10022
US
|
Assignee: |
NIPPON SHINYAKU CO., LTD
Kyoto
JP
|
Family ID: |
32767327 |
Appl. No.: |
12/170859 |
Filed: |
July 10, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10542969 |
Jul 21, 2005 |
|
|
|
12170859 |
|
|
|
|
Current U.S.
Class: |
424/464 |
Current CPC
Class: |
A61P 1/04 20180101; A61K
9/0056 20130101 |
Class at
Publication: |
424/464 |
International
Class: |
A61K 9/20 20060101
A61K009/20 |
Foreign Application Data
Date |
Code |
Application Number |
Jan 23, 2003 |
JP |
2003-012357 |
Claims
1.-5. (canceled)
6. A method of producing an intraorally rapidly disintegrating
tablet, comprising the following steps: a. producing a core
containing an active ingredient and at least one sugar, or
containing a water soluble active ingredient; b. coating the core
with a pharmaceutically acceptable powdered disintegrating agent to
form a granule; and c. tableting the granule.
7. The method of claim 6, wherein the pharmaceutically acceptable
disintegrating agent is a compound selected from the grout)
consisting of crystalline cellulose, low-substituted hydroxypropyl
cellulose, carboxymethyl cellulose, calcium carboxymethyl
cellulose, crospovidone and starch represented by potato starch,
wheat starch, corn starch, rice starch, hydroxypropyl starch,
sodium carboxymethyl starch and partial-pregelantinized starch.
8. The method of claim 6, wherein the sugar is selected from the
group consisting of sugar alcohol represented by mannitol, xylitol,
sorbitol, eryritol, maltitol and maltose; lactose, sucrose,
glucose, and oligosaccharide.
9. The method of claim 6, wherein the average particle diameter of
the granules is in the range of 20 to 1000 .mu.m.
10. The method of claim 6, wherein the thickness of the tablet is
in the range of 1 to 10 mm.
Description
TECHNICAL FIELD
[0001] The present invention relates to an intraorally rapidly
disintegrating tablets having practically unproblematic hardness
and being rapidly disintegrating in the oral cavity. The phrase
"practically unproblematic hardness" refers usually to a hardness
of 35 N or more. The phrase "rapidly disintegrating" refers usually
to disintegration within 1 minute.
BACKGROUND ART
[0002] In recent years, intra orally rapidly disintegrating tablets
have attracted attention as the form of a preparation for improving
the ability of a chemical to be administered, thus improving
patient's compliance etc., and various tablets have been
invented.
[0003] In consideration of excellent solubility in the mouth, many
of conventional intraorally rapidly disintegrating tablets comprise
sugar alcohols such as mannitol and xylitol as excipients. However,
sugar alcohols easily cause obstacles such as sticking (adhesion to
a punch) and binding (adhesion to a die) at the time of tabletting,
and hardness is hardly secured. Accordingly, when intraorally
rapidly disintegrating tablets are produced by using sugar alcohol
as an excipient, a special process and a special apparatus have
been employed wherein, for example, a mixture containing sugar
alcohol is first moistened suitably with water, then
compression-molded under low pressure, dried and thus
tabletted.
[0004] On the one hand, production of intraorally rapidly
disintegrating tablets, which is as close as possible to a usual
method of producing tablets by tabletting dry powder or granules,
is also devised. For example, a method of producing intraorally
rapidly disintegrating tablets which comprises compression-molding
a mixture containing a medicament and a disintegrating agent with
fine sugar alcohol or sugar having an average particle diameter of
30 .mu.m or less as a major ingredient (see WO 97/47287) and a
method of producing intraorally rapidly disintegrating tablets
which comprises compression-molding a major ingredient sugar
alcohol or sugar not particularly fine, to which a disintegrating
agent and cellulose were added (see JP-A 2001-58944), have been
anticipated.
[0005] However, the techniques described above are common in that
dry sugar alcohol is used as a major ingredient, and thus there is
necessity for an increase in the content of a highly
water-repellent lubricant and for limitation of compression
pressure, in order to prevent sticking and binding, and there is a
limit to disintegrating properties and hardness.
DISCLOSURE OF INVENTION
[0006] The object of the present invention is to provide
intraorally rapidly disintegrating tablets which can be produced
easily without any particular problem by a usual method of
producing tablets with a usual tabletting machine, have practically
unproblematic hardness, and disintegrate rapidly in the oral
cavity.
[0007] They found that cores coated with a pharmaceutical
disintegrating agent, wherein the core is a granule containing a
medicament, can be tabletted to give an intraorally rapidly
disintegrating tablet meeting the object described above, and they
completed the present invention.
[0008] The present invention includes, specifically, an intraorally
rapidly disintegrating tablet characterized by being produced by
tabletting cores coated with a pharmaceutical disintegrating agent,
wherein the core is a granule containing a water-soluble medicament
or containing a medicament and a sugar (hereinafter, the
intraorally rapidly disintegrating tablet is referred to as "the
tablet of the present invention").
[0009] The "sugar" which can be used in the present invention is
not particularly limited insofar as it is a pharmaceutically
acceptable sugar. The examples of the sugar include sugar alcohols
such as mannitol, xylitol, sorbitol, erythritol, maltitol and
maltose, lactose, sucrose, glucose, and oligosaccharide. These can
be used singly or as a mixture of two or more thereof.
Particularly, mannitol and lactose are preferable, and combined use
of mannitol and lactose is also preferable.
[0010] It can be said that the "pharmaceutical disintegrating
agent" which can be used in the present invention is a
pharmaceutically acceptable additive capable of promoting
disintegration or dispersion of tablet into secondary particles or
individual particles with saliva. The disintegrating agent is not
particularly limited insofar as it is a disintegrating agent used
in pharmaceutical preparations. The examples of the agent include
crystalline cellulose, low-substituted hydroxypropyl cellulose,
carboxymethyl cellulose (carmellose), calcium carboxymethyl
cellulose (carmellose calcium), crospovidone, and starch
represented by potato starch, wheat starch, corn starch, rice
starch, hydroxypropyl starch (HPS), sodium carboxymethyl starch,
and partial-pregelatinized starch (PCS). These can be used alone or
as a mixture of two or more thereof. Particularly, corn starch is
preferable.
[0011] The average particle diameter of the coated granules
according to the present invention are not particularly limited,
but when a water-sparingly-soluble or water-insoluble medicament is
used, the average particle diameter is suitably 20 to 1000 .mu.m,
preferably in the range of 30 to 500 .mu.m, more preferably in the
range of 50 to 200 .mu.m. The particle diameter is preferably
smaller.
[0012] The medicament is not particularly limited. The examples of
the medicament include the following medicaments. As used herein,
the "water-soluble medicament" refers to a medicament which can be
dissolved in an amount of not less than 0.5 mg/mL, preferably not
less than 1 mg/mL, in water at 20.degree. C.
1. Antipyretic, Analgesic and Antiinflammatory Agents
[0013] Indometacin, aspirin, diclofenac sodium, ketoprofen,
ibuprofen, mefenamic acid, dexamethasone, sodium dexamethasone
sulfate, hydrocortisone, prednisolone, azulene, phenacetin,
isopropyl antipyrine, acetaminophen, benzydamine hydrochloride,
phenylbutazone, flufenamic acid, sodium salicylate, choline
salicylate, sasapirin, clofezone, etodolac, and ferbinac.
2. Antiulcer Agents
[0014] Sulpiride, cetraxate hydrochloride, gefarnate, irsogladine
maleate, cimetidine, ranitidine hydrochloride, famotidine,
nizatidine, roxatidine acetate hydrochloride, and sodium azulene
sulfonate.
3. Coronary Vasodilators
[0015] Nifedipine, isosorbide dinitrate, diltiazem hydrochloride,
trapidil, dipyridamole, dilazep hydrochloride,
methyl-yl)-1,4-dihydropyridine-3-carboxylate, verapamil,
nicardipine, nicardipine hydrochloride, and verapamil
hydrochloride.
4. Peripheral Vasodilators
[0016] Ifenprodil tartrate, cinepazide maleate, cyclandelate,
cinnarizine, and pentoxifylline.
5. Antibiotics
[0017] Ampicillin, amoxiline, cephalexin,
erythromycmethylsuccinate, bacampicillin hydrochloride, minocycline
hydrochloride, chloramphenicol, tetracycline, erythromycin,
griseofulvin, cefditoren pivoxil, azithromycin, and
clarithromycin.
6. Synthetic Antibacterial Agents
[0018] Nalidixic acid, piromidic acid, pipemidic acid trihydrate,
enoxacin, cinoxacin, ofloxacin, norfloxacin, ciprofloxacin
hydrochloride, sulfamethoxazole trimethoprim,
6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)
methyl-1-piperazinyl]-4-oxo-4H[1,3]thiazeto[3,2-a]quinoline-3-carboxylic
acid, and itraconazole.
7. Antispasmodic Agents
[0019] Propantheline bromide, atropine sulfate, oxapium bromide,
timepidium bromide, butylscopolamine bromide, trospium chloride,
butropium bromide, N-methylscopolamine methyl sulfate, and
methyloctatropine bromide.
8. Antitussive and Antiasthmatic Agents
[0020] Theophylline, aminophylline, methyl ephedrine hydrochloride,
procaterol hydrochloride, trimetoquinol hydrochloride, codeine
phosphate, sodium cromoglycate, tranilast, dextromethorphan
hydrobromide, dimemorfan phosphate, clobutinol hydrochloride,
fominoben hydrochloride, benproperine phosphate, tipepidine
hibenzate, eprazinone hydrochloride, clofedanol hydrochloride,
ephedrine hydrochloride, noscapine, carbetapentane citrate,
oxeladin tannate, isoaminil citrate, pranlukast, and fluticasone
propionate.
9. Bronchodilators
[0021] Diprophylin, salbutamolsulfate, chlorprenaline
hydrochloride, formoterol fumarate, orciprenaline sulfate,
pirbuterol hydrochloride, hexoprenaline sulfate, bitolterol
mesilate, clenbuterol hydrochloride, terbutaline sulfate, mabuterol
hydrochloride, fenoterol hydrobromide, and methoxyphenamine
hydrochloride.
10. Diuretics
[0022] Furosemide, acetazolamide, trichlormethiazide,
methylclothiazide, hydrochlorothiazide, hydroflumethiazide,
ethiazide, cyclopentazide, spironolactone, triamterene,
fluothiazide, piretanide, mefruside, etacrynic acid, azosemide, and
clofenamide.
11. Muscle Relaxants
[0023] Chlorphenesin carbamate, tolperisone hydrochloride,
eperisone hydrochloride, tizanidine hydrochloride, mephenesin,
chlorzoxazone, phenprobamate, methocarbamol, chlormezanone,
pridinol mesilate, afloqualone, baclofen, and dantrolene
sodium.
12. Cerebral Metabolism Improving Agent
[0024] Mechlophenoxate hydrochloride.
13. Minor Tranquilizers
[0025] Oxazolam, diazepam, clotiazepam, medazepam, temazepam,
fludiazepam, meprobamate, nitrazepam, chlordiazepoxide, and
quazepam.
14. Major Tranquilizers
[0026] Sulpiride, clocapramine hydrochloride, zotepine,
chlorpromadinone, haloperidol, and risperidone.
15. .beta.-Blockers
[0027] Pindolol, propranolol hydrochloride, carteolol
hydrochloride, metoprolol tartrate, labetalol hydrochloride,
celiprolol hydrochloride, acebutolol hydrochloride, bufetolol
hydrochloride, alprenolol hydrochloride, arotinolol hydrochloride,
oxprenolol hydrochloride, nadolol, bucumolol hydrochloride,
indenolol hydrochloride, thimolol maleate, befunolol hydrochloride,
bupranolol hydrochloride, and carbedilol.
16. Antiarrhythmic Agents
[0028] Procainamidehydrochloride, disopyramide, ajimaline,
quinidine sulfate, aprindine hydrochloride, propafenone
hydrochloride, and mexiletine hydrochloride.
17. Antigout Agents
[0029] Allopurinol, probenecid, colchicine, sulfinpyrazone,
benzbromarone, and bucolome.
18. Anticoagulants
[0030] Ticlopidine hydrochloride, dicumarol, and warfarin
potassium.
19. Antiepileptics
[0031] Phenyloin, sodium valproate, metharbital, and
carbamazepine.
20. Antihistaminics
[0032] Chlorphenylamine maleate, clemastine fumarate, mequitazine,
alimemazine tartrate, and cycloheptadine hydrochloride.
21. Antiemetics
[0033] Difenidol hydrochloride, metoclopramide, domperidone,
betahistine mesilate, and trimebutine maleate.
22. Antihypertensive Agents
[0034] Dimethylaminoethyl Reserpic acid hydrochloride, rescinamine,
methyldopa, prazosin hydrochloride, bunazosin hydrochloride,
clonidine hydrochloride, budralazine, and urapidil.
23. Sympathomimetic Agents
[0035] Dihydroergotamine mesilate, isoproterenol hydrochloride, and
etilefrine hydrochloride.
24. Expectorants
[0036] Bromhexine hydrochloride, carbocysteine, ethylcysteine
hydrochloride, and methylcysteine hydrochloride.
25. Oral Antidiabetic Agents
[0037] Glybenglamide, tolbutamide, glymidine sodium, troglitazone,
rosiglitazone, pioglitazone hydrochloride, and epalrestat.
26. Cardiovascular System Drugs
[0038] Ubidecarenone and ATP-2Na.
27. Iron Preparations
[0039] Ferrous sulfate and dry iron sulfate.
28. Vitamins
[0040] Vitamin B.sub.1, vitamin B.sub.2, vitamin B.sub.6, vitamin
B.sub.12, vitamin C, and folic acid.
29. Therapeutic Agents for Pollakiuria and Urinary Incontinence
[0041] Flavoxate hydrochloride, oxybutynin hydrochloride,
terodiline hydrochloride, 4-diethylamino-1,1-dimethyl-2-butynyl
(.+-.)-.alpha.-cyclohexyl-.alpha.-phenylglycolate hydrochloride
monohydrate.
30. Angiotensin Converting Enzyme Inhibitors
[0042] Enalapril maleate, aracepril, delapril hydrochloride, and
candesartan cilexetil.
31. Agent for Treating Nephritis
[0043]
(3.beta.,4.alpha.)-3,23-Dihydroxy-N-(2-methoxethyl)-18.beta.-olean--
12-en-2 8-amide (hereinafter referred to as Compound A).
32. Immune Suppressor
[0044] Tacrolimus.
33. Antimalignant Tumor Agents
[0045] Paclitaxel, docetaxel, and bicalutamide.
[0046] In the "core being a granule containing a medicament and a
sugar", the compounding ratio of the medicament to the sugar is
determined suitably such that the amount of the sugar is 0.3 to
1000 parts by weight, preferably 0.6 to 500 parts, based on 1 part
of the medicament.
[0047] The amount of the pharmaceutical disintegrating agent
blended varies depending on the particle size of the core, and is
not particularly limited insofar as the core is coated therewith,
but when the amount is too large, the moldability and the ability
of the tablet of the present invention to be administered are
affected, and thus the pharmaceutical disintegrating agent is
applied preferably in a form as thin as possible onto the whole of
the core. The phrase "the core is coated with the pharmaceutical
disintegrating agent" refers to a state in which almost all the
surface of the core is sealed with the pharmaceutical
disintegrating agent.
[0048] The amount of the medicament incorporated into the tablet of
the present invention can be suitably determined depending on the
application method and dose of the medicament to be applied.
[0049] In the tablet of the present invention, a third additive can
be suitably blended in such a range that the disintegrating
property is maintained. The additive includes, for example, a
fluidizing agent, a lubricant, a coloring agent, an aromatic, an
adsorbent, a stabilizer, an antioxidant, a pH adjusting agent, a
surfactant, a buffering agent, a taste corrective, a sweetener, a
foaming agent, a preservative, an acidic-taste agent and a tonic,
and these additives can be contained in a suitable amount depending
on necessity.
[0050] The fluidizing agent includes, for example, long-chain fatty
acids such as stearic acid; monoglycerides, diglycerides and
triglycerides of long-chain (C10 to C22) fatty acids; higher fatty
alcohols such as carnauba wax, polyoxyethylene hydrogenated castor
oil, stearyl alcohol etc., wax such as cetanol; and lecithins,
sodium lauryl sulfate, and these can be contained in an amount of,
for example, 20 wt % or less, in the tablet of the present
invention. The lubricant includes, for example, stearic acid,
magnesium stearate, aluminum stearate, aluminum monostearate,
calcium stearate, stearyl alcohol, talc, titanium oxide, light
silicic anhydride, hydrous silicon dioxide, magnesium silicate,
synthetic aluminum silicate, calcium hydrogen phosphate, sucrose
ester of fatty acids, hydrogenated castor oil, hydrogenated
rapeseed oil, carnauba wax, beeswax, corn starch, polyethylene
glycol, microcrystalline wax, and sodium lauryl sulfate. The
lubricant can be contained in an amount of, for example, 3 wt % or
less in the tablet of the present invention. The coloring agent
includes, for example, iron sesquioxide, yellow iron sesquioxide,
titanium oxide and tar dye. The coloring agent can be contained in
an amount of, for example, 1 wt % or less in the tablet of the
present invention. The aromatic includes, for example, fennel oil,
orange oil, cinnamon oil, clove oil, turpentine oil, peppermint
oil, eucalyptus oil and lemon oil, and can be contained in an
amount of, for example, 3 wt % or less in the tablet of the present
invention. The adsorbent includes, for example, light silicic
anhydride, calcium silicate, anhydrous calcium phosphate and
precipitated calcium carbonate; the stabilizer includes, for
example, cyclodextrin and sodium edetate; the antioxidant includes,
for example, tocopherol, ascorbic acid and cysteine hydrochloride;
the pH adjusting agent includes, for example, phosphate, acetate,
carbonate, citrate, tartrate, fumarate and amino acid salt; the
surfactant includes, for example, sodium lauryl sulfate,
polysorbate 80, polyoxyethylene hydrogenated castor oil and
polyoxyethylene (160) polyoxypropylene (30) glycol; the buffering
agent includes, for example, ascorbic acid, sodium chloride,
potassium chloride and sodium carbonate; the taste corrective
includes, for example, lactose, sucrose, glucose, mannitol,
fructose, sorbitol, aspartame, saccharine, sodium saccharine,
glycyrrhizate, citrate, tartrate, cocoa butter and sodium
glutamate; the sweetener includes, for example, sodium saccharine,
aspartame, dipotassium glycyrrhizate and stevia (sucrose); the
foaming agent includes, for example, sodium bicarbonate and
potassium bicarbonate; the preservative includes, for example,
benzoate, paraoxybenzoate, salicylate and sodium edetate; the
acidic-taste agent includes, for example, citrate, tartrate, malic
acid and ascorbic acid; and the tonic includes, for example,
menthol, peppermint oil, cinnamon oil, fennel oil and camphor.
[0051] The form of the tablet of the present invention is not
particularly limited, and the tablet is formed in shapes such as
round shapes or odd shapes such as ellipse, doughnut etc. The
tablet can be also formed into a scored tablet. The thickness of
the tablet is not particularly limited either, but is suitably 1 to
10 mm, preferably 2 to 8 mm. Generally, the tablet is excellent in
rapid disintegrating properties as the thickness of the tablet is
decreased. The size of the tablet is not particularly limited
either, but the minor axis (or the diameter when the tablet is
circular) is suitably in the range of 6 to 20 mm, preferably 8 to
12 mm.
[0052] The tablet of the present invention can be produced for
example by applying the pharmaceutical disintegrating agent in a
usual manner onto the core being a granule containing a medicament,
then drying it, and tabletting the resulting coated granules in a
usual manner with a fluid bed granulating machine.
[0053] The core being a granule containing a water-soluble
medicament or the core being a granule containing a medicament and
a sugar can be produced for example by granulating and drying a
medicament, a sugar etc. as the starting materials in a usual
manner. The granulation dryer includes, for example, a fluidizing
granulation dryer and a tumbling fluidizing granulation dryer.
[0054] Coating with the pharmaceutical disintegrating agent can
also be conducted after production of the core, but may be
conducted by granulating and drying continuously in an analogous
manner while the core is produced.
[0055] When the core is to be coated with the pharmaceutical
disintegrating agent, a pharmaceutically acceptable binder can be
added in a suitable amount for the purpose of facilitating the
binding of the core to the pharmaceutical disintegrating agent, and
addition of the binder is preferable. The binder is not
particularly limited insofar as it is used in pharmaceutical
preparations. Specific examples include liquid starch glue, methyl
cellulose, hydroxypropyl cellulose (HPC-SSL, HPC-SL, HPC-L etc.),
hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose
(sodium carmellose), gum arabic, gelatin, agar, tragacanth, sodium
alginate, pullulan, polyvinyl pyrrolidone, polyvinyl alcohol and
polyethylene glycol. These can be used alone or as a mixture of two
or more thereof. Particularly, hydroxypropyl cellulose is
preferable. Further, sugar such as lactose can also be incorporated
into the binder. The binder can be added in the state of solution
or slurry.
[0056] The method of mixing the respective components is not
particularly limited, and can be carried out by using a frequently
used mixer.
[0057] The method of tabletting is not particularly limited, and
the method can be conducted by employing a frequently used rotary
tabletting machine, hydraulic pressing machine or single-punch
tabletting machine for example. The tabletting pressure is
fundamentally not different from the molding pressure in usual
tablet production, and is suitably in the range of 3 to 25
kN/cm.sup.2, preferably in the range of 8 to 17 kN/cm.sup.2. The
tablet of the present invention may be produced even if the
tabletting pressure is lower than 3 kN/cm.sup.2 or higher than 25
kN/cm.sup.2, but when the tabletting pressure is too low, the
desired hardness of the tablet may not be obtained. On the other
hand, when the pressure is too high, tablet hardly rapidly
disintegrating in the oral cavity may be obtained.
BEST MODE FOR CARRYING OUT THE INVENTION
[0058] Hereinafter, the present invention is described in more
detail by reference to the Examples, Comparative Examples and Test
Example. As a matter of course, the present invention is not
limited to the following examples.
Example 1
[0059] 6 g of irsogladine maleate, 225 g of D-mannitol (Mannit P,
average particle diameter about 60 .mu.m (manufactured by Towa
Chemical Industry Co., Ltd.), which is used hereinafter unless
otherwise specified) and 159 g of lactose (HMS, average particle
diameter about 60 .mu.m, which is used hereinafter) were fed into a
fluid bed granulation dryer (MP-01 model (manufactured by Powrex),
which is used hereinafter) and granulated while spraying 121.5 g of
purified water (binder solution) containing 4.5 g of hydroxypropyl
cellulose (HPC-SSL (manufactured by Nippon Soda Co., Ltd.), which
is used hereinafter) and 9 g of lactose, thus forming cores, and
when the volume of the binder solution was reduced to 1/3, 45 g of
corn starch (manufactured by Nihon Shokuhin Kako Co., Ltd. and used
hereinafter) was added gradually to the granulation dryer to coat
the cores with the corn starch, followed by a drying step, whereby
coated granules were obtained. 1.5 g of magnesium stearate
(manufactured by Taihei Chemical Industrial Co., Ltd. and used
hereinafter) was added to 300 g of the coated granules to give
mixed powder which was then tabletted (Correct 12HUK, compression
pressure 14.98 kN/cm.sup.2 (149.8 MPa) manufactured by Kikusui
Seisakusho Ltd. and used hereinafter) into the tablets (300
mg/tablet) of 10 mm.phi. in diameter according to the present
invention.
Example 2
[0060] 6 g of irsogladine maleate, 225 g of D-mannitol and 159 g of
lactose were fed into a fluid bed granulation dryer and granulated
while spraying 121.5 g of purified water (binder solution)
containing 4.5 g of hydroxypropyl cellulose and 9 g of lactose, and
when the volume of the binder solution was reduced to 1/3, 45 g of
hydroxypropyl starch (HPS101 manufactured by Freund Sangyo) was
added gradually to the granulation dryer, followed by a drying
step, whereby coated granules were obtained. 1.5 g of magnesium
stearate was added to 300 g of the coated granules to give mixed
powder which was then tabletted into the tablets (300 mg/tablet) of
10 mm.phi. in diameter according to the present invention.
Example 3
[0061] 6 g of irsogladine maleate, 225 g of D-mannitol and 159 g of
lactose were fed into a fluid bed granulation dryer and granulated
while spraying 121.5 g of purified water (binder solution)
containing 4.5 g of hydroxypropyl cellulose and 9 g of lactose, and
when the volume of the binder solution was reduced to 1/3, 45 g of
rice starch (Micropearl manufactured by Shimada Kagaku Co., Ltd.)
was added gradually to the granulation dryer, followed by a drying
step, whereby coated granules were obtained. 1.5 g of magnesium
stearate was added to 300 g of the coated granules to give mixed
powder which was then tabletted into the tablets (300 mg/tablet) of
10 mm.phi. in diameter according to the present invention.
Example 4
[0062] 6 g of irsogladine maleate, 225 g of D-mannitol and 159 g of
lactose were fed into a fluid bed granulation dryer and granulated
while spraying 121.5 g of purified water (binder solution)
containing 4.5 g of hydroxypropyl cellulose and 9 g of lactose, and
when the volume of the binder solution was reduced to 1/3, 45 g of
fine crystalline cellulose (Avicel PH-101 manufactured by Asahi
Kasei Corporation) was added gradually to the granulation dryer,
followed by a drying step, whereby coated granules were obtained.
1.5 g of magnesium stearate was added to 300 g of the coated
granules to give mixed powder which was then tabletted into the
tablets (300 mg/tablet) of 10 mm.phi. in diameter according to the
present invention.
Example 5
[0063] 6 g of irsogladine maleate, 225 g of D-mannitol and 159 g of
lactose were fed into a fluid bed granulation dryer and granulated
while spraying 121.5 g of purified water (binder solution)
containing 4.5 g of hydroxypropyl cellulose and 9 g of lactose, and
when the volume of the binder solution was reduced to 1/3, 45 g of
carboxymethylcellulose (NS-300 manufactured by Gotoku Chemical
Company Ltd.) was added gradually to the granulation dryer,
followed by a drying step, whereby coated granules were obtained.
1.5 g of magnesium stearate was added to 300 g of the coated
granules to give mixed powder which was then tabletted into the
tablets (300 mg/tablet) of 10 mm.phi. in diameter according to the
present invention.
Example 6
[0064] 6 g of irsogladine maleate, 225 g of D-mannitol and 159 g of
lactose were fed into a fluid bed granulation dryer and granulated
while spraying 121.5 g of purified water (binder solution)
containing 4.5 g of hydroxypropylmethyl cellulose (TC-SE
manufactured by Shin-Etsu Chemical Co., Ltd.) and 9 g of lactose,
and when the volume of the binder solution was reduced to 1/3, 45 g
of corn starch was added gradually to the granulation dryer,
followed by a drying step, whereby coated granules were obtained.
1.5 g of magnesium stearate was added to 300 g of the coated
granules to give mixed powder which was then tabletted into the
tablets (300 mg/tablet) of 10 mm.phi. in diameter according to the
present invention.
Example 7
[0065] 6 g of irsogladine maleate, 225 g of D-mannitol and 159 g of
lactose were fed into a fluid bed granulation dryer and granulated
while downwards spraying 121.5 g of purified water (binder
solution) containing 4.5 g of hydroxypropyl cellulose and 9 g of
lactose, and the mixture was subjected to rotating granulation at a
rotor revolution rate of 300 rpm. When the volume of the binder
solution was reduced to 1/3, 45 g of corn starch was added
gradually to the granulation dryer, followed by a drying step,
whereby coated granules were obtained. 1.5 g of magnesium stearate
was added to 300 g of the coated granules to give mixed powder
which was then tabletted into the tablets (300 mg/tablet) of 10 mm
in diameter according to the present invention.
Example 8
[0066] 22.5 g of ambroxol hydrochloride, 217.5 g of D-mannitol and
150 g of lactose were fed into a fluid bed granulation dryer and
granulated while spraying 121.5 g of purified water (binder
solution) containing 4.5 g of hydroxypropyl cellulose and 9 g of
lactose, and when the volume of the binder solution was reduced to
1/3, 45 g of corn starch was added gradually to the granulation
dryer, followed by a drying step, whereby coated granules were
obtained. 1.5 g of magnesium stearate was added to 300 g of the
coated granules to give mixed powder which was then tabletted into
the tablets (300 mg/tablet) of 10 mm in diameter according to the
present invention.
Example 9
[0067] 390 g of D-mannitol was fed into a fluid bed granulation
dryer and granulated while spraying 121.5 g of purified water
(binder solution) containing 4.5 g of hydroxypropyl cellulose and 9
g of lactose, and when the volume of the binder solution was
reduced to 1/3, 45 g of corn starch was added gradually to the
granulation dryer, followed by a drying step, whereby coated
granules were obtained. 3 g of magnesium stearate was added to 300
g of the coated granules to give mixed powder which was then
tabletted into the tablets (300 mg/tablet) of 10 mm.phi. in
diameter according to the present invention.
Example 10
[0068] 390 g of D-mannitol (Mannitol 35, average particle diameter
of about 35 .mu.m, manufactured by Roquette Co., Ltd.) was fed into
a fluid bed granulation dryer and granulated while spraying 121.5 g
of purified water (binder solution) containing 4.5 g of
hydroxypropyl cellulose and 9 g of lactose, and when the volume of
the binder solution was reduced to 1/3, 45 g of cornstarch was
added gradually to the granulation dryer, followed by a drying
step, whereby coated granules were obtained. 3 g of magnesium
stearate was added to 300 g of the coated granules to give mixed
powder which was then tabletted into the tablets (300 mg/tablet) of
10 mm.phi. in diameter according to the present invention.
Example 11
[0069] 225 g of acetaminophen, 60 g of D-mannitol and 105 g of
lactose were fed into a fluid bed granulation dryer and granulated
while spraying 121.5 g of purified water (binder solution)
containing 4.5 g of hydroxypropyl cellulose and 9 g of lactose, and
when the volume of the binder solution was reduced to 1/3, 45 g of
corn starch was added gradually to the granulation dryer, followed
by a drying step, whereby coated granules were obtained. 3 g of
magnesium stearate was added to 300 g of the coated granules to
give mixed powder which was then tabletted into the tablets (300
mg/tablet) of 10 mm.phi. in diameter according to the present
invention.
Example 12
[0070] 225 g of precipitated calcium carbonate, 105 g of D-mannitol
and 60 g of lactose were fed into a fluid bed granulation dryer and
granulated by downwards spraying 121.5 g of purified water (binder
solution) containing 2.25 g of polyvinyl alcohol (EG-05
manufactured by Nippon Gosei Kagaku) and 9 g of lactose, and the
mixture was subjected to rotating granulation at a rotor revolution
rate of 300 rpm. When the volume of the binder solution was reduced
to 1/3, 30 g of corn starch and 15 g of carboxymethyl cellulose
(NS-300 manufactured by Gotoku Chemical Company Ltd.) were added
gradually to the granulation dryer, followed by a drying step,
whereby coated granules were obtained. 1.5 g of magnesium stearate
was added to 300 g of the coated granules to give mixed powder
which was then tabletted into the tablets (300 mg/tablet) of 10
mm.phi. in diameter according to the present invention.
Comparative Example 1
Direct Tabletting Method
[0071] A mixed powder produced by mixing 6 g of irsogladine
maleate, 225 g of D-mannitol, 159 g of lactose, 45 g of corn starch
and 2.2 g of magnesium stearate was tabletted into comparative
tablets (300 mg/tablet) of 10 mm.phi. in diameter.
Comparative Example 2
Method of Internally Adding a Disintegrating Agent
[0072] 6 g of irsogladine maleate, 225 g of O-mannitol, 159 g of
lactose and 45 g of corn starch were fed into a fluid bed
granulation dryer, sprayed with 121.5 g of purified water (binder
solution) containing 4.5 g of hydroxypropyl cellulose and 9 g of
lactose, granulated and dried to give granules. 1.5 g of magnesium
stearate was added to 300 g of the granules to give mixed powder
which was then tabletted into comparative tablets (300 mg/tablet)
of 10 mm.phi. in diameter.
Comparative Example 3
Method of Externally Adding a Disintegrating Agent
[0073] 6 g of irsogladine maleate, 225 g of D-mannitol and 159 g of
lactose were fed into a fluid bed granulation dryer, sprayed with
121.5 g of purified water (binder solution) containing 4.5 g of
hydroxypropyl cellulose and 9 g of lactose, granulated and dried to
give granules. 45 g of corn starch and 1.5 g of magnesium stearate
were added to 255 g of the granules to give mixed powder which was
then tabletted into comparative tablets (300 mg/tablet) of 10
mm.phi. in diameter.
Test Example
[0074] The hardness of the tablets obtained in the Examples and
Comparative Examples, the disintegration time and intraoral
disintegration time in a disintegration test were measured.
Further, the fluidity (good or not) of the tabletting granules, the
binding properties thereof (present or absent), and the adhesion
thereof to the surface of a punch (present or absent) at the time
of production of tablets were observed.
(Hardness) Measured by using a Monsanto hardness meter. 10 tablets
were measured, and the average value was indicated. (Disintegration
time in the disintegration test) Purified water was used as test
fluid, and the disintegration time was confirmed according to the
item of Tablets in Disintegration test in Japanese Pharmacopoeia,
Fourteenth Edition. (Intraoral disintegration time) The time in
which the tablets were disintegrated with only saliva in the oral
cavity was measured by 3 male adults (33-, 40- and
53-year-old).
[0075] The results are shown in Table 1.
TABLE-US-00001 TABLE 1 Tabletting Fluidity obstacles Disintegration
during Adhesion Hardness Disintegration Feel in time in oral
tabletting Creaking to punch (N) time (min) oral cavity cavity
(sec) Example 1 good absent absent 44.1 0.6 good 40-45 Example 2
good absent absent 49.0 0.9 good 45-50 Example 3 good absent absent
54.9 1.0 good 50-60 Example 4 good absent absent 62.7 0.6 good
55-60 Example 5 good absent absent 40.1 0.5 good 30-35 Example 6
good absent absent 40.2 1.0 good 50-60 Example 7 good absent absent
43.1 0.6 good 40-45 Example 8 good absent absent 46.1 1.0 good
35-40 Example 9 good absent absent 45.1 1.0 good 35-40 Example10
good absent absent 51.0 1.0 good 35-40 Example11 good absent absent
50.0 0.6 good 40-45 Example12 good absent absent 42.1 0.9 good
40-50 Comparative bad present present 18.6 0.7 -- -- Example 1
Comparative good present absent 20.6 0.8 -- -- Example 2
Comparative bad present present 35.3 0.8 -- -- Example 3
[0076] As described above, the tablets of the present invention
could be produced excellently without tabletting obstacles, had
hardness without any practical problem, and were disintegrated
rapidly in the oral cavity.
* * * * *